Labetalol S.A.L.F. (Labetalol Hydrochloride)

Labetalol is employed in the management of acute elevations in blood pressure within the cardiovascular disease spectrum.

• Hypertensive emergencies: rapid reduction of dangerously high blood pressure to prevent end‑organ damage.
• Severe hypertension: controlled lowering of sustained high arterial pressure when oral therapy is insufficient.
• Peri‑operative hypertension: stabilization of blood pressure during surgical procedures to reduce cardiovascular risk.

• Labetalol exerts a non‑selective blockade of beta‑adrenergic receptors (β1 and β2) together with selective antagonism of alpha‑1 adrenergic receptors. This dual action reduces heart rate, myocardial contractility, and systemic vascular resistance, leading to a decrease in cardiac output and peripheral blood pressure.

Labetalol may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects

• Dizziness: sensation of light‑headedness or imbalance.
• Headache: mild to moderate pain in the head region.
• Nausea: feeling of queasiness often accompanied by an urge to vomit.
• Flushing: transient redness of the skin, especially on the face.
• Fatigue: unusual tiredness or lack of energy.
• Nasal congestion: blockage or runny nose.

Serious or Rare Side Effects

• Severe hypotension: dangerously low blood pressure requiring immediate intervention.
• Bronchospasm: constriction of airway muscles, particularly in patients with asthma.
• Hepatic dysfunction: abnormal liver enzyme elevations indicating liver stress.
• Heart block: impaired electrical conduction leading to bradycardia.
• Arrhythmia: irregular heart rhythm that may be life‑threatening.
• Anaphylaxis: acute allergic reaction with potential airway compromise.

Prior to initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Blood pressure monitoring: assess and adjust dosage to avoid excessive hypotension.
• Asthma or chronic obstructive pulmonary disease: use cautiously as beta‑blockade may precipitate bronchospasm.
• Hepatic impairment: consider dose reduction or increased monitoring of liver function.
• Concomitant cardiac conduction disorders: avoid in patients with existing heart block without specialist oversight.
• Abrupt discontinuation: taper gradually to prevent rebound hypertension.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Labetalol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Other antihypertensives (e.g., ACE inhibitors, diuretics): additive blood‑pressure lowering effect may cause severe hypotension.
• Calcium channel blockers (especially verapamil): may enhance bradycardia and AV‑node block.
• MAO inhibitors: risk of hypertensive crisis when combined.
• Insulin or oral hypoglycemics: may mask hypoglycemia symptoms.
• Clonidine withdrawal: abrupt cessation can lead to rebound hypertension.

Moderate Interactions (Monitor Closely)

• NSAIDs: may reduce antihypertensive effectiveness.
• Digitalis glycosides: increased risk of bradyarrhythmias.
• Anesthetic agents (e.g., halothane): potential for exaggerated cardiovascular depression.
• Diuretics: may potentiate electrolyte disturbances.
• Antidepressants (tricyclics): possible additive cardiac effects.